1492 Capital Management’s OptimizeRx OPRX Stock Holding History

1492 Capital Management’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-18,681	Closed	-$192K	–	93
2019 Q4	$192K	Sell	18,681 -216,548	-92%	-$2.45M	0.17%	89
2019 Q3	$3.41M	Sell	235,229 -29,956	-11%	-$464K	3.32%	4
2019 Q2	$4.3M	Buy	265,185 +144,006	+119%	+$1.94M	4.02%	4
2019 Q1	$1.54M	Sell	121,179 -11,356	-9%	-$148K	1.3%	24
2018 Q4	$1.45M	Buy	+132,535	New	+$1.96M	1.3%	24

Other funds holding OPRX

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GIPM

G2 Investment Partners Management New York $406M AUM 164.47% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

SST

S Squared Technology New York $264M AUM 73.25% 1-Year Est. Return

1492 Capital Management's OPRX Position: Q1 2020 in Review

1492 Capital Management sold out of OptimizeRx (OPRX) in Q1 2020, closing a stake of 18,681 shares — an estimated $192K sold.

1492 Capital Management first reported a position in OPRX in Q4 2018 and held it in 5 quarters. The position peaked at $4.3M in Q2 2019. 51 funds tracked by Wall St. Rank hold OPRX as of Q1 2020.

1492 Capital Management reported no remaining OptimizeRx position as of Q1 2020 after selling out during the quarter.
1492 Capital Management sold 18,681 OptimizeRx shares in Q1 2020, an estimated $192K.
1492 Capital Management first reported a position in OptimizeRx in Q4 2018 and held it in 5 quarters.
1492 Capital Management's OptimizeRx position peaked at $4.3M in Q2 2019.
51 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2020.

Based on 1492 Capital Management's 13F filing for Q1 2020, filed 12 May 2020.